Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 3/20 | 0.57 |
| ▸ | CES2 | O00748 | 1/20 | 0.54 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.47 |
| ▸ | WNT3A | P56704 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL423798 | 0.86 | DDR1 (0.59) | VNN1CES2DDR1RAB9ACTNNB1 | |
| SCHEMBL4024081 | 0.85 | MEN1 (0.51) | VNN1CES2NAMPTABL1MEN1 | |
| SCHEMBL9602346 | 0.85 | VNN1 (0.61) | VNN1CES2DDR1RAB9AALDH1A1 | |
| SCHEMBL6970291 | 0.84 | CES2 (0.61) | CES2DDR1ALDH1A1CTNNB1WNT3A | |
| SCHEMBL17581950 | 0.84 | CES2 (0.56) | CES2DDR1ALDH1A1CTNNB1WNT3A | |
| SCHEMBL4025014 | 0.83 | DDR1 (0.52) | VNN1CES2DDR1RAB9AALDH1A1 | |
| SCHEMBL6282286 | 0.83 | PTPN1 (0.56) | CES2NAMPTSRD5A2POLB | |
| SCHEMBL11503483 | 0.82 | DDR1 (0.59) | CES2DDR1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL4749524 | 0.82 | CES2 (0.54) | CES2DDR1ALDH1A1CTNNB1WNT3A | |
| SCHEMBL1156959 | 0.80 | CES2 (0.50) | CES2ALDH1A1NPC1TSHRCTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536194-B2 | Pyrazolopyridine derivates | PALAU PHARMA, S.A. (ES) | 2013-09-17 | — | — | US | disclosed |
| EP-1611131-B1 | PYRAZOLOPYRIDINE DERIVATES | PALAU PHARMA SA (ES) | 2010-09-15 | — | — | EP | disclosed |
| US-20090286983-A1 | Pyrazolopyridine Derivates | PALAU PHARMA, S.A. (ES) | 2009-11-19 | — | — | US | disclosed |
| US-20090264446-A9 | Condensed Pyridines as Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2009-10-22 | — | — | US | disclosed |
| EP-0854870-B1 | SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY | MERCK & CO INC (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20090005377-A1 | Pyrazolopyridine Derivates | PALAU PHARMA, S.A. (ES) | 2009-01-01 | — | — | US | disclosed |
| US-20080318977-A1 | Condensed Pyridines as Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2008-12-25 | — | — | US | disclosed |
| US-7468376-B2 | Pyrazolopyridine derivates | PALAU PHARMA, S.A. (ES) | 2008-12-23 | — | — | US | disclosed |
| EP-1833828-A2 | CONDENSED PYRIDINES AS KINASE INHIBITORS | Palau Pharma, S.A. (ES) | 2007-09-19 | — | — | EP | disclosed |
| US-20060167040-A1 | Pyrazolopyridine derivates | J. URIACH Y COMPANIA S.A. (ES) | 2006-07-27 | — | — | US | disclosed |
| EP-1402900-A1 | MEDICINAL COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| EP-1354603-A1 | CONCOMITANT DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2003-10-22 | — | — | EP | disclosed |
| EP-0863757-B1 | 2-SUBSTITUTED ARYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO INC (US) | 2003-03-26 | — | — | EP | disclosed |
| EP-1205478-A1 | p38MAP KINASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2002-05-15 | — | — | EP | disclosed |
| WO-2001057018-A1 | AZAAZULENE INHIBITORS OF P38 MAP KINASE AND TNF-ALPHA | ABBOTT LABORATORIES (US) | 2001-08-09 | — | — | WO | disclosed |
| US-6083949-A | FOR TREATING CANCER IN WHICH RAF KINASE IS IMPLICATED, AS WELL AS COMPOUNDS WHICH INHIBIT, SUPPRESS OR ANTAGONIZE THE PRODUCTION OR ACTIVITY OF CYTOKINES SUCH AS INTERLEUKINS AND TUMOR NECROSIS FACTOR | MERCK & CO., INC. (US) | 2000-07-04 | — | — | US | disclosed |
| EP-0863757-A1 | 2-SUBSTITUTED ARYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | Merck & Co., Inc. (US) | 1998-09-16 | — | — | EP | disclosed |
| EP-0863757-A4 | — | — | 1998-09-16 | — | — | EP | disclosed |
| US-5792778-A | TREATMENT OF CYTOKINE MEDIATED DISEASES | MERCK & CO., INC. (US) | 1998-08-11 | — | — | US | disclosed |
| WO-1997005877-A1 | 2-SUBSTITUTED ARYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 1997-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264446-A9 | Condensed Pyridines as Kinase Inhibitors | MAPK1, MAP4K2, MAP3K1 | VNN1 4268/4885CES2 3068/4885DDR1 1351/4885 |
| US-20080318977-A1 | Condensed Pyridines as Kinase Inhibitors | MAPK1, MAP4K2, MAP3K1 | VNN1 4268/4885CES2 3068/4885DDR1 1351/4885 |
| US-20060167040-A1 | Pyrazolopyridine derivates | MAPK1, MAP4K2, MAP4K3 | VNN1 4142/4885CES2 2320/4885DDR1 2805/4885 |
| US-20090286983-A1 | Pyrazolopyridine Derivates | MAPK1, MAPK4, MAP4K2 | VNN1 4495/4885CES2 3139/4885DDR1 2567/4885 |
| US-20090005377-A1 | Pyrazolopyridine Derivates | MAPK1, MAPK4, MAP4K2 | VNN1 4495/4885CES2 3139/4885DDR1 2567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.